Medical devices, healthcare technology and the business of care
510(k) clearance · K254264

Sofia 2 SARS Antigen+ FIA; Sofia 2 Lyme FIA

Ortho Clinical Diagnostics Inc. (QuidelOrtho) · Decision date Sep 4, 2026

MEDTECHLEDGER EXPLANATIONK254264

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision for K254264 on 2026-09-04, covering the Sofia 2 SARS Antigen+ FIA and the Sofia 2 Lyme FIA from Ortho-Clinical Diagnostics, Inc. (QuidelOrtho). The application was received 12/30/2025 under product code QVF, with subsequent product codes KHO and LSR, in the Microbiology specialty. A SESE finding is a 510(k) clearance, not a PMA approval.

The review document describes the SARS-CoV-2 component as a rapid lateral flow immunoassay for qualitative detection of SARS-CoV-2 nucleoprotein in anterior nasal swab specimens, and the Lyme component as a rapid lateral flow immunoassay for differential detection of human IgM and IgG antibodies to Borrelia burgdorferi. The document states that performance characteristics were established from August 2021 to November 2022 and that labeling supports the finding of substantial equivalence. The available excerpts do not give the full intended-use wording, clinical performance figures, or the specific changes that distinguish this submission from its predicate.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Microbiology
Decision date
Sep 4, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K254264
Regulatory pathway
510(k) premarket notification
Product code
QVF
Decision code
SESE
Decision date
Sep 4, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Simple Point-Of-Care Device To Directly Detect Sars-Cov-2 Viral Targets From Clinical Specimens In Near-Patient Settings.

Product code
QVF
FDA device class
2

FDA decision timeline

  1. K254264 received

    Application receipt date recorded by FDA.

  2. K254264 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code QVF

Product / regulatory recordCompanyPathwayDecision dateSource
BD Diagnostic Solutions / Becton, Dickinson & Company510(k) clearanceOct 27, 2026FDA
CorDx, Inc.510(k) clearanceJun 1, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Ortho Clinical Diagnostics Inc. (QuidelOrtho)

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
San Diego, CA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records